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Abstract
Background: Prior studies suggested low density lipoprotein particle (LDLP) size is a predictor
of atherosclerosis. Knowledge of effects of lipid lowering drugs on lipoprotein subclasses is useful.
We treated subjects with hyperlipidemia sequentially with statins and fibrates, the 2 main classes
of lipid lowering therapy and studied changes in NMR lipoprotein subclasses.
Methods: 35 subjects (21 males; 60 ± 12 y) were enrolled in a crossover study. Subjects had
baseline lipid profile & apoB. Lipoprotein subclasses, particle numbers and diameters were assessed
with NMR spectroscopy. Subjects were randomized to simvastatin 20 mg or fenofibrate 200 mg.
Repeat testing was done at 12 weeks. After 6 week washout, subjects were started on alternate
drug for 12 weeks with pre/post tests.
Results: Both therapies resulted in expected changes in lipids and apoB. Decreases in total
cholesterol, LDL and apoB were greater with simvastatin. Fenofibrate led to small increase in HDL.
Both therapies decreased LDLP. Reduction in LDLP was greater with simvastatin (32%, p < .001)
compared to fenofibrate (17%; p = .036 vs pre; p = .027 vs simvastatin end). Fenofibrate resulted
in 17% rise in large LDLP (p = .06 vs pre) and 32% drop in small LDLP (p = .007 vs pre). Simvastatin
led to decrease in both LDLP fractions (19% large LDLP; p = .001 vs fenofibrate end; 34% small
LDLP, p = .019 vs pre). With fenofibrate, LDLP size increased from 20.4 nm to 20.8 nm (p = .037).
There was no change in LDLP size with simvastatin. There was 18% increase in HDL particle
number (HDLP) with fenofibrate (p = .05). There were no changes in HDLP with simvastatin. There
were no changes in HDLP size with either drug. Pre- and post-therapy LDLP/HDLP ratio was
similar with fenofibrate but was reduced by simvastatin (p = .045).
Conclusion: Simvastatin reduced LDLP across all subclasses with no effect on size. Simvastatin had
no effect on HDLP. Fenofibrate had weak effect on LDLP number but increased LDLP size by raising
large LDLP and reducing small LDLP. Fenofibrate had weak effect on HDLP number with no change
in size. Importantly, net atherogenic to antiatherogenic lipoprotein ratio (LDLP/HDLP) was
reduced by simvastatin but not by fenofibrate.
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Background
Prospective, placebo controlled primary and secondary
prevention trials have shown that cholesterol lowering
reduces cardiovascular morbidity and mortality[1,2].
Most of the emphasis has been placed on lowering of low
density lipoprotein (LDL) cholesterol. Although it is usu-
ally thought of as a single entity, LDL is actually com-
prised of multiple different subclasses that differ in size,
density, physicochemical composition, buoyancy and
metabolic behaviour. All these factors influence their
atherogenicity[3,4]. In a detailed analysis of the factors
associated with angiographic progression/regression in
the Familial Atherosclerosis Treatment Study, Zambon et
al showed that LDL buoyancy accounted for 37% of the
variance whereas apolipoprotein B (a measure of number
of LDL particles) only accounted for 12%[5]. Further-
more, different LDL profiles may warrant different thera-
pies. The same investigators showed that subjects with
predominantly large and buoyant LDL require aggressive
reduction of LDL cholesterol whereas those with Familial
Combined Hypercholesterolemia require LDL cholesterol
lowering as well as reduction in the number of small,
dense LDL particles[6].
Different techniques can be used to quantify LDL into dif-
ferent classes. These include fast protein liquid chroma-
tography, nuclear magnetic resonance (NMR)
spectroscopy, disc polyacrylamide electrophoresis, den-
sity gradient ultracentrifugation and gradient gel electro-
phoresis[7]. Among these, NMR spectroscopy has the
advantage of being able to measure simultaneously parti-
cle concentration, lipid mass-weighted particle diameter
and the predominant class of both LDL and high density
lipoprotein (HDL)[8].
3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A)
reductase inhibitors (statins) and fibric acid derivatives
(fibrates) are two widely used agents for treatment of dys-
lipidemia[1,9]. Statins have been shown to improve cardi-
ovascular mortality and outcomes in multiple clinical
trials. Detailed analyses of angiographic trials of statin
therapy have yielded important insights. In patients with
CAD and "normal" cholesterol, the progression of disease
as defined by progressive angiographic narrowing has
been shown to correlate with concentration of intermedi-
ate density lipoprotein (IDL) cholesterol and HDL choles-
terol but not with LDL cholesterol[10]. The NHLBI-II trial
reported that subjects with greater angiographic "stabil-
ity" had significantly greater reductions in total LDL mass,
small dense LDL and IDL mass[11]. Among the success-
fully treated subjects in the MARS trial, triglyceride rich
lipoprotein levels were the predominant predictors of
progression[12]. In the STARS trial, reduction in small,
dense LDL was the best predictor of angiographic
improvement[13]. In a detailed analysis, investigators
from the Stanford Coronary Risk Intervention Project
showed that despite almost identical LDL cholesterol at
baseline and comparable diet and drug induced reduction
in levels of LDL cholesterol, patients with subclass pattern
B (predominantly small dense LDL), but not those with
pattern A (predominantly large, buoyant LDL) showed
progression of atherosclerosis[14]. These studies illustrate
the importance of LDL particle size to progression of
atherosclerosis and adverse cardiac outcomes.
Fibrates are another major class of lipid modifying drug.
Clinical trials of fibrates have revealed conflicting results.
Of the 5 major fibrate trials in the modern era, only the
VA-HIT study with gemfibrozil showed a significant
reduction in major cardiovascular events as well as
stroke[9]. Detailed analysis of the lipid profile in the VA-
HIT trial showed that both LDL particle numbers and
HDL particle numbers were independent predictors of
adverse outcome whereas LDL cholesterol and HDL cho-
lesterol were not[15].
Knowledge of the effects of different classes of lipid low-
ering agents on lipoprotein subclasses, particularly on the
particle concentration and size, is essential. In this study
we treated subjects with hypercholesterolemia sequen-
tially with statins and fibrates, the two main classes of
lipid lowering drugs and studied the changes in lipopro-
tein subclasses and average particle diameters with an
NMR method.
Methods
Thirty-five subjects (21 males (60%), mean age 60 ± 12
years (median 59 years)). were enrolled. Subjects were
recruited from a Lipid Clinic at a tertiary care referral hos-
pital. None had coronary artery disease or other vascular
disease by history. All participants underwent baseline
clinical and laboratory assessment including lipid profile,
apoB, lipoprotein subclasses, particle numbers and aver-
age particle diameters, high sensitivity C-reactive protein,
glucose, creatinine and homocysteine. Subjects were then
randomized in a 1:1 fashion to either initial therapy with
simvastatin 20 mg daily or fenofibrate (lipidil micro) 200
mg daily for 12 weeks. Repeat final laboratory assessment
was carried out at 12 weeks. After a washout period of 6
weeks, subjects were started on the alternate drug for 12
weeks with pre and post laboratory testing. A lipid profile
was carried out after 6 weeks in the simvastatin group. If
LDL-C was ≥ 2.5 mmol/L, the simvastatin dose was
increased to 40 mg daily. This occurred in 3 subjects. The
study was approved by the Providence Healthcare/Univer-
sity of British Columbia ethics review board. All subjects
gave written informed consent.
Lipoprotein lipids, Apo B, homocysteine, glucose were
measured by standard clinical methods in a clinical labo-BMC Clinical Pharmacology 2008, 8:10 http://www.biomedcentral.com/1472-6904/8/10
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ratory (St. Paul's Hospital, Vancouver, Canada). C-reac-
tive protein was measured with a high sensitivity
immunoassay (Immulite 2000, Siemens Medical Solu-
tions Diagnostics, Tarrytown, New York). Lipid sub-
classes, particle numbers and average particle diameters
were measured by NMR spectroscopy (Liposcience Inc,
Raleigh, North Carolina). Details of NMR analyses have
been published previously[15]. In brief, the particle con-
centrations of lipoprotein subclasses of different sizes are
derived from the measured amplitudes of the distinct
lipid methyl group NMR signals they emit. For simplicity
of analysis very low density lipoprotein particles (VLDL-
P) were divided into large VLDL-P (60–200 nm), medium
VLDL-P (35–60 nm) and small VLDL-P (27–35 nm). LDL
particle (LDL-P) subclasses were divided into intermedi-
ate density lipoprotein-particles (23–27 nm), large LDL-P
(21.2–23.0 nm) and small LDL-P (18.0–21.2 nm). HDL
particle (HDL-P) subclasses were divided into large HDL-
P (8.8–13.0 nm), medium HDL-P (8.2–8.8 nm) and
small HDL-P (7.3–8.2 nm). These subgroups are consist-
ent with previous studies using NMR spectroscopy. The
lipid mass-weighted particle diameters of VLDL, LDL and
HDL were also obtained with NMR spectroscopy. The pro-
portions of subjects with predominantly large LDL (aver-
age particle diameter >21.2 nm) and small LDL (average
particle diameter ≤ 21.2 nm) were determined.
Statistical analysis
There were no significant differences in any of the lipid
variables at either the initiation or the end of treatment for
either drug regardless of which drug was used first. There-
fore the data were combined into the 2 drug treatment
groups for final analyses. Data was visually inspected for
normality. Data with obvious skewness were log trans-
formed. Results were expressed as mean ± SD or median
with interquartile range where appropriate. The primary
outcomes were comparison of the change from baseline
to end of 12 weeks between simvastatin and fenofibrate.
Student t-test or Mann-Whitney U test was used for com-
parison between variables. A p-value of <0.05 was consid-
ered significant for the comparisons.
Results
Subject characteristics
The risk factor profile, laboratory parameters and baseline
lipid profiles were listed in Table 1. Subjects were at rela-
tively low risk for cardiovascular events. There were no sig-
nificant changes in glucose, insulin, creatinine,
fibrinogen, C-reactive protein with either simvastatin or
fenofibrate treatment.
Lipid profile
At baseline, all subjects had relatively high total choles-
terol, LDL-C and apoB. Both fenofibrate and simvastatin
therapy resulted in significant changes in all parameters of
the lipid profile as well as apoB (Figure 1). However, the
decreases in total cholesterol, LDL-C and apoB were sig-
nificantly greater with simvastatin therapy. Fenofibrate
therapy led to a marginally higher increase in HDL choles-
terol only.
NMR lipoprotein particle numbers and sizes
At baseline, the majority of VLDL-P were in the medium
(45% before fenofibrate therapy, 52% before simvastatin
therapy) and small subfractions (49% before fenofibrate
therapy, 41% before simvastatin therapy) (figure 2A).
Both fenofibrate and simvastatin reduced total VLDL-P
with only minor differences between the two therapies
(50% after fenofibrate therapy, 39% after simvastatin
therapy). All subclasses of VLDL-P were reduced with both
fenofibrate and simvastatin therapy with no difference
between the two drugs. There were no changes in VLDL-P
diameter with either therapy (figure 3). It should be noted
that VLDL particles degrade during freeze thaw cycles. As
our samples were frozen prior to being thawed and ana-
lyzed for different lengths of time, we cannot be certain of
any changes observed in our subjects with either of the
drugs. We have included the VLDL particle results for
completeness only.
Almost all subjects had a predominance of small dense
LDL-P at baseline. Fibrate therapy resulted in no change
(88% to 86%). With simvastatin therapy, all subjects had
predominance of small dense LDL-P (from 96% at base-
line to 100% with treatment). Both fenofibrate and simv-
astatin decreased total LDL-P concentration (figure 2B).
With fenofibrate, there was a significant 21% decrease in
LDL-P concentration (from 2156 ± 596 nmol/L to 1794 ±
634 nmol/L, p = 0.036). With simvastatin, LDL-P
decreased by 32% (from 2194 ± 619 nmol/L to 1553 ±
461 nmol/L, p < 0.001). The reduction in LDL-P was sig-
nificantly greater in the simvastatin arm compared to the
fenofibrate arm (p = 0.027). Fibrate therapy resulted in a
significant 17% increase in the large LDL-P fraction but a
Table 1: Baseline characteristics of the subjects
Glucose (mmol/L) 5.5 ± 1.2
Insulin (pmol/L) 55.5 ± 46.9
HOMA 302 ± 259
Creatinine (mmol/L) 85 ± 17
C reactive protein (mg/dl) 2.7 ± 3.9
Fibrinogen (g/L) 3.3 ± 0.6
Weight (kg) 82.1 ± 12.8
Height (cm) 170.2 ± 9.8
Body mass index 28.5 ± 4.2
Lipid profile
Total Cholesterol (mmol/L) 6.7 ± 1.3
LDL-C (mmol/L) 4.4 ± 1.1
HDL-C (mmol/L) 1.1 ± 0.4
Triglycerides (mmol/L) 2.6 ± 1.4
ApoB (g/L) 1.4 ± 0.3BMC Clinical Pharmacology 2008, 8:10 http://www.biomedcentral.com/1472-6904/8/10
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32% decrease in the small LDL-P fraction. Simvastatin
therapy led to a decrease in both LDL-P fractions (-19% in
large LDL-P; -34% in small LDL-P). At the end of therapy,
66% of the LDL-P was in the small subfraction after fenof-
ibrate therapy while 77% of the LDL-P was in the small
subfraction after simvastatin therapy.
Before fenofibrate therapy, the mean LDL particle size at
baseline was 20.4 ± 1.0 nm (figure 3). At completion of
therapy, the mean LDL particle size increased to 20.8 ± 0.5
nm (p = 0.037). Before simvastatin treatment, the mean
LDL particle size at baseline was 20.2 ± 0.8 nm (p = NS vs
fenofibrate baseline), at completion, the mean LDL parti-
cle size was unchanged at 20.4 ± 0.8 nm (p = NS vs base-
line).
There was an increase of 18% in total HDL particle
number with fenofibrate (31.9 ± 6.3 nmol/L vs 36.3 ± 9.9
nmol/L; p = 0.05, figure 2C) primarily due to an increase
in the medium HDL-C fraction. There were no changes in
total HDL particle number with simvastatin (33.5 ± 7.8
nmol/L vs 34.0 ± 7.9 nmol/L; p = NS). There were no
changes in HDL particle size with either fenofibrate or
simvastatin (figure 3).
Atherogenic to anti-atherogenic lipoprotein particle ratio
The pre- and post-treatment LDL-P to HDL-P ratio was
similar with fenofibrate therapy (68.9 ± 20.0 vs 61.2 ±
68.0 p = NS, figure 4). However, the pre- and post-treat-
ment LDL-P to HDL-P ratio was significantly reduced by
simvastatin (72.3 ± 44.2 vs 49.7 ± 28.2 p = 0.045, figure
4).
Changes in lipid profile with simvastatin and fenofibrate therapy Figure 1
Changes in lipid profile with simvastatin and fenofibrate therapy. All lipid parameters including apoB improve signifi-
cantly with both simvastatin and fenofibrate treatment. However, the reduction in total cholesterol, LDL-C and apoB (as indi-
cated by the uppermost bar) were significantly higher with simvastatin than fenofibrate. * p < 0.05 vs baseline; † p < 0.05 vs 
other drug.BMC Clinical Pharmacology 2008, 8:10 http://www.biomedcentral.com/1472-6904/8/10
Page 5 of 8
(page number not for citation purposes)
Discussion
Our study of dyslipidemia subjects demonstrated that
simvastatin and fenofibrate modify lipid profile in differ-
ent manners. Simvastatin predominantly reduced LDL-P
concentration across all LDL subclasses with no change in
particle diameter. Simvastatin had no effect on either
HDL-P concentration or diameter. Fenofibrate had a
much weaker effect on LDL-P concentration but increased
LDL-P diameter; it also had a moderate effect on increas-
ing relative HDL-P concentration but did not change the
HDL-P diameter. Importantly, the net overall atherogenic
to anti-atherogenic lipoprotein ratio (as reflected by the
LDL-P:HDL-P ratio) was significantly reduced by simvas-
tatin but was not affected by fenofibrate. This finding has
not been reported before.
Our results are consistent with previous investigations of
fenofibrate therapy using NMR spectroscopy. Ikewaki et al
studied 20 subjects with hypertriglyceridemia[16]. They
found a 97% increase in large LDL-P and 42% decrease in
small LDL-P while the overall LDL-P particle number was
only decreased by 10% and the LDL-P diameter increased.
There were decreases in large HDL-P and increases in
small and medium HDL-P with a significant increase in
overall HDL-P number (27%) and HDL-P diameter
decreased. These same investigators found similar
changes in a subsequent study with bezafibrate suggesting
the changes in LDL-P and HDL-P subclasses distribution,
concentration and diameter were not drug specific but
related to the effects of this drug class[17]. Furthermore,
May et al found a decrease in LDL pattern B and an
increase in buoyant (large) LDL particles in diabetic sub-
jects with mixed dyslipidemia treated with fenofi-
brate[18]. Both HDL2 and HDL3 particles increase with
fenofibrate.
Simvastatin therapy significantly improved the lipid pro-
file. Detailed analyses of the lipid subclasses showed
reductions in both the large and small LDL subfractions.
There were no changes in average LDL particle size. Simv-
astatin therapy did not alter HDL particle number or par-
ticle size. Two previous studies had evaluated the effects of
simvastatin on lipoprotein subfractions. Milller et al
found a dose dependent reduction in LDL-P, IDL-P and
VLDL-P as well as a dose dependent increase in large HDL-
P[19]. May et al found a decrease in both LDL pattern B
and buoyant LDL particles with simvastatin[18]. There
were no significant changes with HDL2 and HDL3 parti-
cles. Other investigators have studied changes in lipid
subfractions with other statins. Soedamah-Muthu et al
studied 122 subjects with type 2 diabetes and dyslipi-
demia[20]. They compared changes in lipid subfractions
between atorvastatin with placebo. Their findings in the
atorvastatin arm are similar to our results with simvasta-
tin.
Three previous studies have compared statin with fibrates
in the same group of subjects. Melonovsky et al compared
29 subjects with combined hyperlipidemia between ator-
vastatin and fenofibrate[21]. They measured lipid profile,
apoB, apoA1 and LDL particle size with gradient gel elec-
trophoresis. Their findings are similar to ours. Frost et al
compared 13 subjects with type 2 diabetes mellitus and
mixed hyperlipidemia with atorvastatin and fenofi-
brate[22]. LDL particle size was determined by isopycknic
density gradient ultracentrifugation. They found that ator-
vastatin reduced all LDL subclasses whereas fenofibrate
shifted LDL subclasses from small, dense LDL (-31%) to
intermediate dense LDL (+36%). Winkler et al studied 6
males with combined hyperlipidemia with atorvastatin
and fenofibrate[23]. LDL particle was fractionated with
Changes in particle numbers of lipid subfractions with simvastatin and fenofibrate therapy Figure 2
Changes in particle numbers of lipid subfractions with simvastatin and fenofibrate therapy. A: VLDL subfractions 
– no significant changes were seen in VLDL particle number with either simvastatin or fenofibrate therapy. B: LDL subfractions 
– both simvastatin and fenofibrate reduce total LDL particle numbers. The reduction was higher with simvastatin than fenofi-
brate (as illustrated by the uppermost bar). There was a significant increase in the large LDL-P subfraction with fenofibrate. 
Small LDL particle numbers tend to reduce with both therapies. C: HDL subfractions – fenofibrate but not simvastatin increase 
total HDL particle numbers. * p < 0.05 vs baseline; ** p < 0.05 vs baseline; † p < 0.05 vs other drug.BMC Clinical Pharmacology 2008, 8:10 http://www.biomedcentral.com/1472-6904/8/10
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ultracentrifugation. Treatment with fenofibrate resulted in
increases in the larger LDL-1, LDL-2 and LDL-3 fractions
and decreases in the more dense LDL-4, LDL-5 and LDL-6
fractions. Treatment with atorvastatin resulted in
decreases in all 6 LDL fractions. Our study is larger than
the previous studies. Furthermore, by using the NMR
spectroscopy technology, we were able to provide more
details with respect to changes in not only LDL subclasses,
but also HDL subclasses as well as changes in LDL-P to
HDL-P ratio.
Fibrates induce a moderate reduction in LDL-cholesterol
with an increase in LDL particle size. The way fenofibrate
increases LDL particle size is of interest. Possible mecha-
nisms include preferential decrease in small LDL-P num-
bers, preferential increase in large LDL-P numbers or a
combination of both. Our results suggest both an increase
in large LDL-P numbers and a decrease in small LDL-P
numbers.
LDL particle size has been proposed as a marker of
increased risk of future adverse cardiac events. However,
the utility of LDL particle size as a predictor can be ques-
tioned. Almost all of the studies that implicate LDL parti-
cle size as an independent variable for either the presence
or progression of atherosclerosis have not taken LDL par-
ticle number into account. The VA-HIT study evaluated
both simultaneously with combined cardiac death or
nonfatal myocardial infarction as an end point[15]. LDL
particle size did not emerge as an independent predictor
but LDL particle number was a predictor of adverse out-
comes. Similarly, HDL particle size did not predict out-
come but total HDL particle number was a predictor. The
EPIC-Norfolk study evaluated LDL particle number and
Changes in mean particle diameters of lipid subfractions with simvastatin and fenofibrate therapy Figure 3
Changes in mean particle diameters of lipid subfractions with simvastatin and fenofibrate therapy. Fenofibrate 
but not simvastatin therapy significantly increase mean LDL particle diameter. There were no changes with either drugs on 
mean VLDL or HDL particle diameters. * p < 0.05 vs baseline.BMC Clinical Pharmacology 2008, 8:10 http://www.biomedcentral.com/1472-6904/8/10
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size in apparently healthy males and females[24]. They
showed that LDL particle number is a predictor of devel-
opment of coronary artery disease but LDL particle size is
not related to outcome. We showed that simvastatin but
not fenofibrate significantly alters the atherogenic to anti-
atherogenic lipoprotein LDL-P/HDL-P ratio. This fits with
the results of previous studies that showed that statins
improve cardiovascular outcomes while the results with
fibrates as a class are, at best, mixed.
In fact, our results and other studies call into question the
utility of fibrates as a therapeutic class of LDL modifying
agents. Although current thought suggests that large LDL
particles are less atherogenic than small LDL particles,
recent findings have shown that both large and small LDL
particles are atherogenic. In the VA-HIT study, the hazard
ratio of large LDL particles is similar to that of small LDL
particles[15]. In the Multi-Ethnic Study of Atherosclerosis,
both large and small LDL particles were independently
associated with carotid intima media thickness (IMT)
[25]. Furthermore, on a per particle basis, large LDL parti-
cles were associated with a greater difference in IMT than
small LDL particles. We found that while both fenofibrate
and simvastatin lowered small LDL particles to a similar
degree, fenofibrate actually increased the number of large
LDL particles whereas simvastatin decreased the number
of large LDL particles. The increase in large LDL particles
is partially responsible for the failure of fenofibrate to
alter the LDL-P/HDL-P ratio. The VA-HIT study also
showed that Gemfibrozil increased the number of large
LDL particles. Thus we believe that fibrates as a class
increase large LDL-P and do not lower LDL-P/HDL-P
ratio. These data would argue that fibrates have only a very
limited role (if any at all) in modifying LDL-P and LDL
cholesterol.
There are a number of limitations to this study. The
number of subjects is relatively small and small differ-
ences will not be detectable. We also used a cross over
design with all subjects receiving both therapies. This
allowed us to determine the effects of both therapies on
all subjects. There was a long washout period between the
two therapies. There were no significant differences in
baseline lipid profile or lipoprotein subclasses at the initi-
ations of either the first or second drug. Nonetheless, we
cannot completely exclude a carryover effect from the first
to the second drug. The two therapies were applied in dif-
ferent manners in this study. With simvastatin, we treated
to a LDL-cholesterol target (2.5 mmol/L) and thus differ-
ent subjects received different doses of the drug. With
fenofibrate, the same dose was applied to all subjects.
However, this reflects how these therapies are used in cur-
rent practice.
Conclusion
We assessed the effects of both simvastatin and fenofi-
brate therapy in a group of subjects with dyslipidemia. We
found that both therapies are associated with significant
changes in lipid profile. Simvastatin reduced LDL choles-
terol and apoB while fenofibrate increased HDL choles-
terol. The effects of simvastatin and fenofibrate on LDL
particle subfractions were different. Specifically, simvasta-
tin reduced the total number of LDL particles by reducing
both large and small LDL particles. Fenofibrate reduced
the number of small LDL particles but increased the
number of large LDL particles. The overall LDL-P/HDL-P
ratio was reduced by simvastatin but not changed with
fenofibrate therapy. Our results combined with previous
reports call into question the overall role of fibrates in
modifying LDL-P, LDL cholesterol and atherosclerosis.
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